New Discoveries in Cancer and Heart Disease

MCED PUBLICATIONS

This list of MCED publications is not complete.  It is being updated to include recent MCED publications.  We're sorry for the inconvenience.  April 20, 2018.

  • Weisenthal, L. M. (2010). Antitumor and anti-microvascular effects of sorafenib in fresh human tumor culture  in comparison with other putative tyrosine kinase inhibitors.  J Clin Oncol 28, 2010 (suppl; abstr e13617) 
  • Weisenthal, L., H. Liu, Rueff-Weisenthal, C. (2010). "Death of human tumor endothelial cells in vitro through a probable calcium-associated mechanism induced by bevacizumab and detected via a novel method."  Nature Precedings 28 May 2010.  http://precedings.nature.com/documents/4499/version/1. 
  • Weisenthal, Larry . Endothelial Massive Calcium Accumulation Death (MCAD): Mechanism, Target, and Predictive Biomarker for Anti-Angiogenic Therapy. 13th international symposium on anti-angiogenic therapy: recent advances  and future directions in basic and clinical cancer research. LaJolla, CA. February 2011 Available from Nature Precedings  http://dx.doi.org/10.1038/npre.2011.6647.1  
  • Larry Weisenthal, Summer Williamson, Cindy Brunschwiler, and Constance Rueff-Weisenthal,Bevacizumab-induced tumor calcifications can be elicited in glioblastoma microspheroid culture and represent massive calcium uptake death (MCAD) of tumor endothelial cells. 14th International Anti-Angiogenesis  Symposium, LaJolla CA, Feb 2012. Available from Nature Precedings  http://dx.doi.org/10.1038/npre.2012.7069.1  (2012).
  • Larry Weisenthal, Summer Williamson, Cindy Brunschweiler, and Constance Rueff-Weisenthal. Massive calcium accumulation death (MCAD) of endothelial cells as a putative mechanism for bevacizumab anti-angiogenesis and acquired resistance to bevacizumab http://weisenthalcancer.com, 4th International Anti-Angiogenesis  Symposium, LaJolla CA, Feb 2013